Condition: Adenocarcinoma of the Stomach · Adenocarcinoma of Esophagogastric Junction · HER2-positive Gastric Cancer · Sponsor: Yu jiren
This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative chemotherapy with FLOT regimen and trastuzumab in combination with toripalimab in participants with resectable HER2 positive locally advanced gastric or esophagogastric junction adenocarcinoma.
This description comes directly from the study's public registry record.
Jiren Yu · 0086-0571-87237931 · yujr0909@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital, College of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
| The Second Affiliated Hospital, College of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Not Yet Recruiting |
| Huzhou Central Hospital | Huzhou, Zhejiang, China | Not Yet Recruiting |
| Lishui Central Hospital | Lishui, Zhejiang, China | Not Yet Recruiting |
| Ningbo First Hospital | Ningbo, Zhejiang, China | Not Yet Recruiting |
| Ningbo Medical Center LiHuiLi Hospital | Ningbo, Zhejiang, China | Not Yet Recruiting |
| Ningbo Second Hospital | Ningbo, Zhejiang, China | Not Yet Recruiting |
| Taizhou Hospital | Taizhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05715931